Drug maker Lupin Wednesday said it has received final approval from the US health regulator to market the generic version of Mycobutin capsules of Pharmacia and Upjohn Company used in treating advance HIV infection.
The approval from the US Food and Drug Administration is for Rifabutin Capsules USP, in strength of 150 mg, said Lupin in a statement.
According to IMS Mat, Mycobutin Capsules had annual sales of $18.6 million in the US.
